AMRX R&D to Revenue
Amneal Pharmaceuticals Inc Class A · R&D to Revenue
AMRX R&D to Revenue
Latest reported6.17%period ending
AMRX FY R&D/Revenue (13.59% → 6.17%)
Latest values, visible window
High-resolution chart · PNG
AMRX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 6.1673% | |
| 6.8259% | |
| 8.1363% | |
| 9.4317% | |
| 10.0094% | |
| 9.565% | |
| 12.4379% | |
| 12.655% | |
| 18.5689% | |
| 20.1082% | |
| 15.7997% | |
| 13.586% |